^
Association details:
| Biomarker: | KIF5B-MET fusion + MET-CDR2 fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report Liu LF, Deng JY, Lizaso A, Lin J, Sun S. Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report. World J Clin Cases 2022; 10(8): 2529-2536 [DOI: 10.12998/wjcc.v10.i8.2529]
Published date:
03/16/2022
Excerpt:
A 46-year-old woman was diagnosed with poorly differentiated NSCLC (T4N3M1)….Targeted sequencing revealed the detection of two concurrent MET fusions, KIF5B-MET and novel MET-CDR2. Crizotinib was initiated at a dose of 250 mg twice daily. Within 4 wk of crizotinib therapy, repeat computed chromatography revealed a dramatic reduction in primary and metastatic lesions, assessed as partial response.
DOI:
10.12998/wjcc.v10.i8.2529
